Search PubMed⌕ Search

Biomedical subjects

H Shao

Publications and source records attributed to H Shao.

81 records · Page 5Linked to original sources
PubMed1992

Analysis of human herpesvirus 6 glycoproteins recognized by monoclonal antibody OHV1.

A virus-specific glycoprotein (gp) from human herpes-virus 6 (HHV-6) was studied using the anti-HHV-6 monoclonal antibody OHV1. Immunoprecipitation with extracts from infected cells revealed that the antibody recognized four glycosylated proteins (gps) with Mrs of 106K, 102K, 65K and 63K under reducing conditions. However, only two gps, of 106K (gp106) and 102K, were detected under non-reducing conditions. Pulse-chase experiments revealed that gp65 and gp63 were cleavage products of gp106 and gp102. When infected cells were treated with tunicamycin, none of these gps was detected. With endo-beta-N-acetylglucosaminidase H (endo H) and endo-beta-N-acetylglucosaminidase F (endo F) treatment, gp106 and gp102 disappeared. Moreover, gp65 and gp63 were not affected by endo H treatment but were sensitive to endo F treatment. These data suggest that sugar residues of gp106 and gp102 are high-mannose type N-linked oligosaccharides, whereas those of gp65 and gp63 are complex type N-linked oligosaccharides.

Antibodies, Monoclonal↗
PubMed1991

Additivity of prostaglandin F2 alpha-1-isopropyl ester to timolol in glaucoma patients.

The effect on intraocular pressure (IOP) of adding prostaglandin F2 alpha-1-isopropyl ester (PGF2 alpha-IE) to timolol was studied in 21 eyes of 13 patients with newly diagnosed primary open-angle glaucoma that was inadequately controlled with timolol alone. After at least 2 weeks of twice daily timolol 0.5% therapy, PGF2 alpha-IE, 0.5 microgram in 30 microliters, was topically applied twice daily at 8 AM and 8 PM, 5 minutes before each timolol dose, for 7 days. Intraocular pressures were measured before timolol treatment, and at 8 AM, 8:30 AM, 12 PM, 2 PM, and 4 PM on the day before the addition of PGF2 alpha-IE, and on day 1 and on day 7 of combined therapy. Mean IOP was 39 +/- 2 mmHg (+/- standard error) before timolol therapy and 31 +/- 2 mmHg after at least 2 weeks of treatment with timolol alone. A significant (P = 0.004) further reduction of IOP was first observed 4 hours after the first dose of PGF2 alpha-IE, which was maintained throughout the duration of combined therapy. During the last day of combined treatment and at 12 hours after the final dose, IOP was reduced a mean of 6 to 9 mmHg (mean, 9.0 +/- 1.5 mmHg at 12 hours) below baseline values obtained with timolol alone. These results indicate that adding PGF2 alpha-IE in patients treated with timolol causes a further reduction of IOP that may prove to be clinically useful in glaucoma therapy.

Adult↗
PubMed1991

[Molecular cloning of lipopolysaccharide genes of the Vibrio cholerae in E. coli HB101].

A genomic library of the V. cholerae 178 (Eltor biotype, Ogawa serotype) was constructed by using cosmid pHC 79 as a cloning vector. We screened the library with immune agglutination test and colonies solid phase ELISA. 13 positive recombinants which could express the O antigen of the V. cholerae lipopolysaccharide (LPS) were acquired. The LPS was then extracted from a positive recombinant PMM-VO 38 by using hot phenol-water method. It was found that purified LPS specifically reacted to antisomatic serum against the V. cholerae. The restriction endonucleases analysis showed that the molecular weight of the recombination cosmid PMM-VO 38 was about 46 kb.

Antigens, Bacterial↗
PubMed1991

[Effect of lipoperoxide on catabolism of protein in burns in rats].

The effects of lipid peroxide on protein catabolism after severe burn injury are studied. Burned rats (30% TBSA III) were divided randomly into two groups: group A (N = 120) received I. M. injection of bovine serum albumin (BSA) served as control; group B (N = 146), the treated group, receiving I. M. injection of superoxide dismutase (SOD) and catalase (CAT). It was found that in PBD 5, 7, 9, 11, 3-Methyl histidine (3-Mehis) excretion was significantly lower in group B than in group A (P less than 0.01); and that in group B cumulative urinary nitrogen (UN) excretion and cumulative nitrogen balance in the eleven-day period after burns were significantly lower than in group A (P less than 0.01); On PBD 12, serum GOT and GPT were higher significantly in group A than that in group B (P less than 0.05). Besides, in group B the total nitrogen content in liver and gastrocnemius muscle on PBD 12 was significantly higher than in group A (P less than 0.05). These findings suggest that a certain relationship exists between lipoperoxide and increased protein catabolism after severe burns. SOD and CAT, the oxygen radical scavengers, can reduce protein catabolism to a certain extent, and protect the hepatic function from being injured.

Animals↗
PubMed1991

[The effect of topical metoprolol on intraocular pressure].

A single dose of topical 2% metoprolol, a new beta adrenergic antagonist, induced a significant IOP reduction in 20 normal volunteers (40 eyes) and 20 patients (40 eyes) with primary open angle glaucoma. The IOP of the latter 40 eyes remained significantly below the pretreatment levels during 6 months of continued application of the drug b.i.d. No changes were noted in pupil size, blood pressure, or heart rate, indicating that metoprolol is an effective ocular hypotensive.

Adult↗
PubMed1988

The effect of prostaglandin F2 alpha on intraocular pressure in normotensive human subjects.

Hypotensive and other ocular effects were studied for 24 hr after topical application of prostaglandin F2 alpha as the tromethamine salt (PGF2 alpha) in 45 normotensive human subjects. After baseline intraocular pressure (IOP) measurements, 62.5 micrograms, 125 micrograms and 250 micrograms of PGF2 alpha dissolved in 50 microliter of saline was applied to one eye of 15 subjects for each dose tested. Contralateral control eyes received 50 microliter of saline. As compared with the IOP of the contralateral control eyes, topical application of 62.5 micrograms PGF2 alpha caused a significant IOP reduction at 1-12 hr, with a maximal IOP reduction of 2.2 mm Hg at 2 hr. Treatment with 125 micrograms of PGF2 alpha lowered IOP significantly at 1-21 hr, with a maximal reduction of 3.1 mm Hg at 9 hr. Administration of 250 micrograms PGF2 alpha produced a significant reduction of IOP, which lasted for at least 24 hr. A maximal IOP reduction of 2.9 mm Hg occurred at 7 hr. Pupillary diameter was not altered. Aqueous flare and anterior chamber cellular response were not seen in any of the eyes of the subjects at any time after topical application of 62.5-250 micrograms PGF2 alpha. The drug caused side effects consisting of reddened skin of lower lid, ocular irritation, conjunctival hyperemia and headache.

Administration, Topical↗
PubMedDate not supplied

A novel applicator for low-dose-rate brachytherapy of gynecological cancers.

The standard low-dose-rate (LDR) delivery system utilized in the definitive management of patients with cervical carcinoma involves an intrauterine tandem and a pair of vaginal colpostats (ovoids). This well-known application system may deliver inadequate dosage if the tumor extends to the lower vaginal mucosa. During the gauze packing of the ovoids, either operator error or narrowing of the vaginal apex can result in mal-alignment of the colpostats and subsequent inadequate dosing to the ecto-cervix. A novel vaginal cylinder has been designed to address these concerns. Beginning January 1, 2001, patients with cancer of the cervix, endometrium, or vagina requiring LDR brachytherapy have been enrolled into an institutionally sanctioned clinical trial. As of May 31, 2001, a total of 11 patients have been entered but only 10 were successfully implanted with the test device. Patient follow-up has ranged from 0.81 years to 1.2 years (median: 0.96 years). Using our study applicator, all patients received within 10% of the preimplant prescribed dose to tumor. Also, no one had cumulative dosage that exceeded 10% of the maximum allowed dose to the critical normal tissues. Thus far, all study patients have had no clinical evidence of persistence/recurrence of disease or complications from treatment. The preliminary results presented herein clearly demonstrate the feasibility of this novel LDR vaginal cylinder in the treatment of a variety of clinical situations involving gynecological cancers. Our institutional trial is continuing.

Adult↗
PubMedDate not supplied

Synthesis, crystal structure and conformation in solution of four stereoisomeric cyclo-lanthionine derivatives.

The synthesis of the four stereoisomeric cyclo-lanthionine derivatives: [formula: see text] (where AlaL denotes one end of the lanthionine unit) was carried out on a Kaiser-oxime resin starting from orthogonally protected lanthionine units. The peptide ring was prepared in 79-85% yield via amide bond formation by utilizing the method of peptide cyclization on an oxime resin (PCOR). The crystal and molecular structures of the protected cyclic dipeptides have been determined by X-ray diffraction techniques. The two cyclic lanthionine derivatives with chiralities of [R,S] and [S,R] crystallized in the orthorhombic space group P2(1)2(1)2(1) and the [R,R]- and [S,S]-cyclo-lanthionine derivatives in the monoclinic space group C2. The structures were solved by direct methods and refined to an R factor of 0.0368-0.0573. The ring amide bonds in all four compounds are cis, while the urethane group is trans and extended. The NMR spectra of the four stereoisomers in DMSO-d6 were used to determine their conformation in solution. The analysis of the NMR data with constrained distance geometry search showed the same conformational features in solution as in the crystalline state.

Alanine↗